Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
Journal of Clinical Oncology - United States
doi 10.1200/jco.2010.29.7010
Full Text
Open PDFAbstract
Available in full text
Date
December 10, 2010
Authors
Publisher
American Society of Clinical Oncology (ASCO)